No­var­tis qui­et­ly hands top­i­cal treat­ment for rare dis­ease to Life­Max — lat­est in a string of out-li­cens­ing deals

The steady stream of out­ward deals flow­ing from No­var­tis made a rare dis­ease turn to­day.

Pa­lo Al­to-based Life­Max Lab­o­ra­to­ries has li­censed BPR277, a clin­i­cal stage …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER